SNDX Syndax Pharmaceuticals (SNDX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001395937
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
134
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $949.4K priced
What the filings say about SNDX
Insiders, 180 days
-$2.1M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Syndax Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Syndax Pharmaceuticals Inc insiders sold a net $2.1M of stock across 104 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 30 earlier Form 4 trades (code P or S) here by this insider (30 sales), the last on Jun 1, 2026.
- The trade is 6.7% of the 484,843 shares held after it.
- 1 other insider sold within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Metzger Michael A sold about $784.8K of SNDX on Jul 8, 2026; 1 other insider sold within 30 days and 134 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Jun 11, 2026.
- The trade is 51.3% of the 60,885 shares held after it.
- 2 other insiders sold within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of R&D, CMO Botwood Nicholas A.J. sold about $566.6K of SNDX on Jun 12, 2026; 2 other insiders sold within 30 days and 134 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 16, 2025.
- The trade is 56.3% of the 60,885 shares held after it.
- 2 other insiders sold within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of R&D, CMO Botwood Nicholas A.J. sold about $617.0K of SNDX on Jun 11, 2026; 2 other insiders sold within 30 days and 134 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Feb 9, 2026.
- The trade is 0.8% of the 139,252 shares held after it.
- 2 other insiders sold within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Goldan Keith A. sold about $22.4K of SNDX on Jun 1, 2026; 2 other insiders sold within 30 days and 134 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Feb 9, 2026.
- The trade is 1.4% of the 484,843 shares held after it.
- 2 other insiders sold within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Metzger Michael A sold about $130.0K of SNDX on Jun 1, 2026; 2 other insiders sold within 30 days and 134 funds added in the latest 13F quarter.104 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.1M over 180 days
below 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
134 funds bought in last quarter
more than 79% of Pharma & Biotech
Revenue
+627.8% year over year
more than 94% of Pharma & Biotech
Margin
-165.6% net margin
below 63% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.4% of the float short (float per yahoo 2026-10-27) · 7.6 days to cover · settled 2026-10-15
more than 95% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch SNDX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-9.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SNDX: institutional holders (13F)
13F holdings, latest reported quarter
9,020,006 sh
$197.2M
8,050,959 sh
$176.0M
5,861,265 sh
$128.1M
5,658,424 sh
$123.7M
4,045,094 sh
$88.4M
Congress trades in SNDX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SNDX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MICHAEL METZGER
Filed 2026-07-08
$752.4K
SNDX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.4%
Columbia Variable Portfolio - Select Small Cap Value Fund
$1.8M position · as of 2026-06-30
1.3%
Franklin Biotechnology Discovery Fund
$11.1M position · as of 2026-07-31
1.0%
Columbia Select Small Cap Value Fund
$3.8M position · as of 2026-05-31
0.9%
BNY Mellon Small Cap Value Fund
$2.5M position · as of 2026-06-30
0.8%
Small Cap Portfolio
$3.0M position · as of 2026-06-30
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
1 active
3
Phase 2
2 active
1
Phase 3
1 active
1
Not applicable
0 active
6
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Michael AMetzger
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$7.7M
$1.6M
$2.6M
-41%
-7%
2023
$9.1M
$5.2M
$3.0M
-3%
-6%
2021
$3.9M
$2.9M
$2.6M
-2%
+0%
2020
$2.2M
$7.6M
$2.5M
+153%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.1M sold by insiders over 180 days, 134 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SNDX financials
Revenue growth
+627.8%
XBRL, annual
Net margin
-165.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$252.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SNDX
| FY Dec 2025 | $172.6M |
| FY Dec 2024 | $23.7M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $139.7M |
| FY Dec 2021 | $139.7M |
| Jun 2026 | $72.8M |
| Mar 2026 | $64.9M |
| Dec 2025 | $68.7M |
| Sep 2025 | $45.9M |
| Jun 2025 | $38.0M |
| Mar 2025 | $20.0M |
| Dec 2024 | $7.7M |
| Sep 2024 | $12.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-87.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SNDX
| FY Dec 2025 | -165.4% |
| FY Dec 2024 | -1,346% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -106.9% |
| FY Dec 2021 | +17.8% |
| Jun 2026 | -67.8% |
| Mar 2026 | -65.8% |
| Dec 2025 | -98.9% |
| Sep 2025 | -132.4% |
| Jun 2025 | -189.3% |
| Mar 2025 | -423.3% |
| Dec 2024 | -1,227% |
| Sep 2024 | -673.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$220.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SNDX
| FY Dec 2025 | -$323.2M |
| FY Dec 2024 | -$275.1M |
| FY Dec 2023 | -$160.8M |
| FY Dec 2022 | -$133.9M |
| FY Dec 2021 | $28.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
22.78x
current debt only, 2026-06-30; equity 2026-06-30
Debt to equity SNDX
| FY Dec 2025 | 5.32x |
| FY Dec 2024 | 1.19x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 22.78x |
| Mar 2026 | 8.26x |
| Dec 2025 | 5.32x |
| Sep 2025 | 2.98x |
| Jun 2025 | 2.18x |
| Mar 2025 | 1.60x |
| Dec 2024 | 1.19x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.64x
TTM operating cash flow over current debt only, 2026-06-30
Cash flow to debt SNDX
| FY Dec 2025 | -0.94x |
| FY Dec 2024 | -0.80x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.64x |
| Mar 2026 | -0.81x |
| Dec 2025 | -0.94x |
| Sep 2025 | -0.90x |
| Jun 2025 | -0.88x |
| Mar 2025 | -0.83x |
| Dec 2024 | -0.80x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-255.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SNDX
| FY Dec 2025 | -161.8% |
| FY Dec 2024 | -75.7% |
| FY Dec 2023 | -41.0% |
| FY Dec 2022 | -34.1% |
| FY Dec 2021 | +7.5% |
| Jun 2026 | -255.9% |
| Mar 2026 | -189.5% |
| Dec 2025 | -161.8% |
| Sep 2025 | -129.3% |
| Jun 2025 | -113.2% |
| Mar 2025 | -93.7% |
| Dec 2024 | -75.7% |
| Sep 2024 | -81.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-34.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SNDX
| FY Dec 2025 | -45.5% |
| FY Dec 2024 | -47.7% |
| FY Dec 2023 | -37.7% |
| FY Dec 2022 | -31.5% |
| FY Dec 2021 | +6.6% |
| Jun 2026 | -34.0% |
| Mar 2026 | -43.7% |
| Dec 2025 | -45.5% |
| Sep 2025 | -63.8% |
| Jun 2025 | -62.4% |
| Mar 2025 | -56.0% |
| Dec 2024 | -47.7% |
| Sep 2024 | -72.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SNDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-35.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SNDX
| FY Dec 2025 | -53.0% |
| FY Dec 2024 | -57.8% |
| FY Dec 2023 | -45.0% |
| FY Dec 2022 | -33.8% |
| FY Dec 2021 | +7.4% |
| Jun 2026 | -35.7% |
| Mar 2026 | -47.9% |
| Dec 2025 | -53.0% |
| Sep 2025 | -76.3% |
| Jun 2025 | -73.9% |
| Mar 2025 | -66.2% |
| Dec 2024 | -57.8% |
| Sep 2024 | -88.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SNDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.2B
market value at close 2026-10-26 on 2026-07-31 shares, plus current debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value SNDX
| FY Dec 2025 | $2.0B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $1.2B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.9B |
| Mar 2026 | $2.3B |
| Dec 2025 | $2.0B |
| Sep 2025 | $1.6B |
| Jun 2025 | $1.0B |
| Mar 2025 | $1.2B |
| Dec 2024 | $1.3B |
| Sep 2024 | $1.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-18.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield SNDX
| FY Dec 2025 | -17.7% |
| FY Dec 2024 | -24.5% |
| FY Dec 2023 | -10.7% |
| FY Dec 2022 | -8.7% |
| FY Dec 2021 | +2.7% |
| Jun 2026 | -11.4% |
| Mar 2026 | -13.5% |
| Dec 2025 | -17.7% |
| Sep 2025 | -23.5% |
| Jun 2025 | -37.6% |
| Mar 2025 | -27.1% |
| Dec 2024 | -24.5% |
| Sep 2024 | -15.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SNDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $0 |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M |
| EPS (diluted) | -3.29 | -3.72 | -2.98 | -2.46 |
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M |
| Cash | $134.9M | $154.1M | $295.4M | $74.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
SNDX Stock Sonar score 6/7 axes
Find similar shapesCompareSNDX ranks highest on growth (94th percentile) and institutional and government (79th), and lowest on insider conviction (14th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SNDX filings, in plain words
Are Syndax Pharmaceuticals insiders buying or selling SNDX?
In the 180 days to 2026-10-28, Syndax Pharmaceuticals insiders were net sellers, a net $2.1M across purchases and sales reported on Form 4, by 3 sellers.
Read the full summary
In the 180 days to 2026-10-28, Syndax Pharmaceuticals insiders were net sellers of SNDX, a net $2.1M across purchases and sales reported on Form 4 by 3 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
